Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13718-13727
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13718
Adjuvant therapy for gastric cancer: Current and future directions
Marcus Foo, Trevor Leong
Marcus Foo, Trevor Leong, Division of Radiation Oncology and Cancer Imaging and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria 3002, Australia
Trevor Leong, University of Melbourne, Melbourne 3010, Australia
Author contributions: Foo M and Leong T contributed equally to this work.
Correspondence to: Trevor Leong, Associate Professor, Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, St Andrews Place East Melbourne, Victoria 3002, Australia. trevor.leong@petermac.org
Telephone: +61-3-9656-1111 Fax: +61-3-9656-1424
Received: October 29, 2013
Revised: July 6, 2014
Accepted: July 29, 2014
Published online: October 14, 2014
Processing time: 352 Days and 11.5 Hours
Core Tip

Core tip: Surgery remains the cornerstone of curative therapy in gastric cancer. However, a large proportion of patients are diagnosed with locally advanced disease, resulting in poor survival. Randomized trials have now established either post-operative chemoradiotherapy or perioperative chemotherapy as standard adjuvant therapies in the Western world. There remain, however, significant differences in the approach to management between the West and East. In Asia, extended resection followed by adjuvant chemotherapy represents the standard of care. This review discusses the evidence supporting current standard adjuvant therapy in gastric cancer, as well as recent and ongoing trials investigating novel (neo)adjuvant approaches.